Peptide Loading Complex in Cancer: From Peptide Translocation, Editing, and Loading into MHC-I to a Potential Therapeutic Target

Abstract

The peptide-loading complex (PLC) is a pivotal endoplasmic reticulum (ER) protein machinery that facilitates peptide translocation, editing, and loading onto major histocompatibility complex class I (MHC-I) to allow recognition of infected or transformed cells by CD8⁺ cytotoxic T lymphocytes (CTLs). PLC comprises the peptide transporter complex formed of transporters associated with antigen processing (TAP1/2), the adapter protein tapasin, chaperones such as calreticulin (CRT) and ERp57, and β2-microglobulin (β2M), ensuring the proper assembly of MHC-I/peptide complexes for subsequent antigen presentation on the cell surface. In cancer, tumorigenesis often involves structural malfunctions and transcriptional, post-transcriptional, and epigenetic modifications that impair the functioning of PLC proteins. This eventually causes loss of MHC-I cell-surface expression, failure of antigen presentation, and escape from CTL-mediated immunosurveillance. Although malfunctions in antigen-processing machineries are well known, herein we provide an overview of the PLC as a major determinant of tumor immune escape and a potential therapy target. In this regard, recent evidence indicates that individual PLC components not only affect MHC-I/antigen presentation but also influence tumor development and progression, immune evasion, and treatment resistance. Furthermore, we explore existing or evolving therapeutic approaches to recover/reprogram PLC functions such as IFN-γ-induced PLC activation, TAP1 and tapasin gene therapy, epigenetics-based treatments such as DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi), and microRNA targeting strategy.

Keywords

Peptide-loading complex / MHC-I / Cancer immunotherapy / TAP / Tapasin / Calreticulin / ERp57 / β2-Microglobulin / Antigen processing

References

[1] Janeway CA Jr, Travers P, Walport M, et al. The major histocompatibility complex and its functions. Immunobiology: The Immune System in Health and Disease. New York: Garland Science; 2001.

[2] Wijdeven RH, Luk SJ, Schoufour TAW, et al.. Balanced epigenetic regulation of MHC class I expression in tumor cells by the histone ubiquitin modifiers BAP1 and PCGF1. J Immunol, 2024, 212(3): 446-454

[3] Guillaume J, Perzolli A, Boes M. Strategies to overcome low MHC-I expression in paediatric and adult tumours. Immunother Adv, 2024, 4: Itad028

[4] Wieczorek M, Abualrous ET, Sticht J, et al.. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol, 2017, 8: 292

[5] Altenburg AF, Morley JL, Decatris SM, et al.. Reanalysis of immunopeptidomics datasets provides mechanistic insight into TAPBPR-mediated peptide editing on HLA-A, -B and -C molecules. Wellcome Open Res, 2024, 9: 113

[6] Shi K, Li QY, Zhang YQ, et al.. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma. Aging, 2023, 15(20): 11067-11091

[7] Jurewicz M, Nanaware P, Stern L. MHC class II peptide loading regulates selection and function of regulatory T cells. Mol Immunol, 2022, 150: 3

[8] Van Kaer L, Wu L, Joyce S. Mechanisms and consequences of antigen presentation by CD1. Trends Immunol, 2016, 37(11): 738-754

[9] Robert J, Najafi-Majd E. Evolutionary perspective of nonclassical MHC class I and innate-like T cells relevance in immune surveillance. Cells, 2025, 14(20): 1592

[10] Brunnberg J, Barends M, Frühschulz S, et al.. Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation. Proc Natl Acad Sci U S A, 2024, 121(22): e2321600121

[11] Purcell AW, Elliott T. Molecular machinations of the MHC-I peptide loading complex. Curr Opin Immunol, 2008, 20(1): 75-81

[12] Sun Y, Young MC, Woodward CH, et al.. Universal open MHC-I molecules for rapid peptide loading and enhanced complex stability across HLA allotypes. Proc Natl Acad Sci U S A, 2023, 120(25): e2304055120

[13] Ackerman AL, Cresswell P. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J Immunol, 2003, 170(8): 4178-4188

[14] Barends M, Koller N, Schölz C, et al.. Dynamic interactome of the MHC I peptide loading complex in human dendritic cells. Proc Natl Acad Sci U S A, 2023, 120(25): e2219790120

[15] Jongsma MLM, Guarda G, Spaapen RM. The regulatory network behind MHC class I expression. Mol Immunol, 2019, 113: 16-21

[16] Cano F, Bye H, Duncan LM, et al.. The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation. EMBO J, 2012, 31(17): 3596-3606

[17] Neefjes JJ, Hämmerling GJ, Momburg F. Folding and assembly of major histocompatibility complex class I heterodimers in the endoplasmic reticulum of intact cells precedes the binding of peptide. J Exp Med, 1993, 178(6): 1971-1980

[18] Antón LC, Yewdell JW. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J Leukoc Biol, 2014, 95(4): 551-562

[19] Ferrington DA, Gregerson DS. Immunoproteasomes. The Proteasomal System in Aging and Disease. Amsterdam: Elsevier; 2012:75–112.

[20] Parcej D, Tampé R. ABC proteins in antigen translocation and viral inhibition. Nat Chem Biol, 2010, 6(8): 572-580

[21] Cresswell P, Bangia N, Dick T, et al.. The nature of the MHC class I peptide loading complex. Immunol Rev, 1999, 172(1): 21-28

[22] Lan BH, Becker M, Freund C. The mode of action of tapasin on major histocompatibility class I (MHC-I) molecules. J Biol Chem, 2023, 299(4): 102987

[23] Jiang J, Taylor DK, Kim EJ, et al.. Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation. Nat Commun, 2022, 13(1): 5470

[24] Wearsch PA, Cresswell P. Selective loading of high-affinity peptides onto major histocompatibility complex class I molecules by the tapasin-ERp57 heterodimer. Nat Immunol, 2007, 8(8): 873-881

[25] Momburg F, Roelse J, Howard JC, et al.. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature, 1994, 367(6464): 648-651

[26] Sabbatino F, Liguori L, Polcaro G, et al.. Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients. Int J Mol Sci, 2020, 21(19): 7295

[27] Leone P, Shin EC, Perosa F, et al.. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst, 2013, 105(16): 1172-1187

[28] Rock KL, Reits E, Neefjes J. Present yourself! by MHC class I and MHC class II molecules. Trends Immunol, 2016, 37(11): 724-737

[29] Lee MY, Jeon JW, Sievers C, et al.. Antigen processing and presentation in cancer immunotherapy. J Immunother Cancer, 2020, 8(2): e001111

[30] Margulies DH, Jiang J, Ahmad J, et al.. Chaperone function in antigen presentation by MHC class I molecules-tapasin in the PLC and TAPBPR beyond. Front Immunol, 2023, 14: 1179846

[31] Nguyen TT, Chang SC, Evnouchidou I, et al.. Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1. Nat Struct Mol Biol, 2011, 18(5): 604-613

[32] Blees A, Januliene D, Hofmann T, et al.. Structure of the human MHC-I peptide-loading complex. Nature, 2017, 551(7681): 525-528

[33] Arshad N, Cresswell P. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J Biol Chem, 2018, 293(25): 9555-9569

[34] Morozov GI, Zhao H, Mage MG, et al.. Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing. Proc Natl Acad Sci U S A, 2016, 113(8): E1006-E1015

[35] Xu H, Song K, Da LT. Dynamics of peptide loading into major histocompatibility complex class I molecules chaperoned by TAPBPR. Phys Chem Chem Phys, 2022, 24(20): 12397-12409

[36] Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol, 2021, 12: 636568

[37] Schrörs B, Lübcke S, Lennerz V, et al.. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model. Oncotarget, 2017, 8(17): 28312-28327

[38] Erdogdu IH. MHC class 1 and PDL-1 status of primary tumor and lymph node metastatic tumor tissue in gastric cancers. Gastroenterol Res Pract, 2019, 2019: 4785098

[39] Chang CC, Pirozzi G, Wen SH, et al.. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem, 2015, 290(44): 26562-26575

[40] Maeurer M, Gollin S, Storkus W, et al.. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res Off J Am Assoc Cancer Res, 1996, 2(4): 641-652

[41] Van Kaer L, Ashton-Rickardt PG, Ploegh HL, et al.. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4−8+ T cells. Cell, 1992, 71(7): 1205-1214

[42] Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature, 1992, 356(6368): 443-446

[43] Williams AP, Peh CA, Purcell AW, et al.. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity, 2002, 16(4): 509-520

[44] Yan J, Parekh VV, Mendez-Fernandez Y, et al.. In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med, 2006, 203(3): 647-659

[45] York IA, Brehm MA, Zendzian S, et al.. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci U S A, 2006, 103(24): 9202-9207

[46] Cromme FV, Airey J, Heemels MT, et al.. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med, 1994, 179(1): 335-340

[47] Tanaka K, Tsuchikawa T, Miyamoto M, et al.. Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol, 2012, 40(4): 965-974

[48] Ayshamgul H, Ma H, Ilyar S, et al.. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J, 2011, 124(3): 341-346

[49] Freund-Brown J, Chirino L, Kambayashi T. Strategies to enhance NK cell function for the treatment of tumors and infections. Crit Rev Immunol, 2018, 38(2): 105-130

[50] Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers, 2020, 12(7): 1760

[51] Menon AG, Morreau H, Tollenaar RAEM, et al.. Down-regulation of HLA-a expression correlates with a better prognosis in colorectal cancer patients. Lab Investig, 2002, 82(12): 1725-1733

[52] Lorenzi S, Forloni M, Cifaldi L, et al.. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One, 2012, 7(10): e46928

[53] Maleno I, López-Nevot MA, Cabrera T, et al.. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother, 2002, 51(7): 389-396

[54] Kriegsman BA, Vangala P, Chen BJ, et al.. Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression. J Immunol, 2019, 203(7): 1999-2010

[55] Yoshihama S, Roszik J, Downs I, et al.. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A, 2016, 113(21): 5999-6004

[56] Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al.. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun, 2018, 9(1): 248

[57] Fonsatti E, Nicolay HJ, Sigalotti L, et al.. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res, 2007, 13(11): 3333-3338

[58] Sun T, Li Y, Yang W, et al.. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer, 2019, 10(23): 5638-5645

[59] Shen C, Li M, Duan Y, et al.. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Front Immunol, 2023, 14: 1170207

[60] Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol, 2018, 8: 92

[61] Moufarrij S, Srivastava A, Gomez S, et al.. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci Rep, 2020, 10: 3470

[62] Jongsma MLM, Neefjes J, Spaapen RM. Playing hide and seek: tumor cells in control of MHC class I antigen presentation. Mol Immunol, 2021, 136: 36-44

[63] Cerami E, Gao J, Dogrusoz U, et al.. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2012, 2(5): 401-404

[64] Seliger B, Ritz U, Abele R, et al.. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res, 2001, 61(24): 8647-8650

[65] Chen HL, Gabrilovich D, Tampé R, et al.. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet, 1996, 13(2): 210-213

[66] Howe C, Garstka M, Al-Balushi M, et al.. Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO J, 2009, 28(23): 3730-3744

[67] Marijt KA, Blijleven L, Verdegaal EME, et al.. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med, 2018, 215(9): 2325-2337

[68] de Waard AA, Verkerk T, Jongsma MLM, et al.. PAKC: a novel panel of HLA class I antigen presentation machinery knockout cells from the same genetic origin. Eur J Immunol, 2021, 51(3): 734-737

[69] Doorduijn EM, Sluijter M, Querido BJ, et al.. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest, 2016, 126(2): 784-794

[70] de Waard AA, Verkerk T, Hoefakker K, et al.. Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens. iScience, 2021, 24(2): 102051

[71] Johnsen AK, Templeton DJ, Sy M, et al.. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol, 1999, 163(8): 4224-4231

[72] Alimonti J, Zhang QJ, Gabathuler R, et al.. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol, 2000, 18(5): 515-520

[73] Henle AM, Nassar A, Puglisi-Knutson D, et al.. Downregulation of TAP1 and TAP2 in early stage breast cancer. PLoS One, 2017, 12(11): e0187323

[74] Dissemond J, Busch M, Kothen T, et al.. Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett, 2004, 203(2): 225-231

[75] Ozbas-Gerceker F, Bozman N, Gezici S, et al.. Association of TAP1 and TAP2 gene polymorphisms with hematological malignancies. Asian Pac J Cancer Prev, 2013, 14(9): 5213-5217

[76] Tabassum A, Samdani MN, Dhali TC, et al.. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. J Mol Med (Berl), 2021, 99(9): 1293-1309

[77] Garrido G, Schrand B, Rabasa A, et al.. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nat Commun, 2019, 10(1): 3773

[78] Lou Y, Basha G, Seipp RP, et al.. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin Cancer Res, 2008, 14(5): 1494-1501

[79] Padariya M, Kote S, Mayordomo M, et al.. Structural determinants of peptide-dependent TAP1–TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations. Comput Struct Biotechnol J, 2021, 19: 5072-5091

[80] Sokol L, Koelzer VH, Rau TT, et al.. Loss of tapasin correlates with diminished CD8⁺ T-cell immunity and prognosis in colorectal cancer. J Transl Med, 2015, 13: 279

[81] Shionoya Y, Kanaseki T, Miyamoto S, et al.. Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. Oncoimmunology, 2017, 6(2): e1274476

[82] Colangelo T, Polcaro G, Ziccardi P, et al.. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis, 2016, 7(2): e2120

[83] Toquet C, Jarry A, Bou-Hanna C, et al.. Altered Calreticulin expression in human colon cancer: maintenance of Calreticulin expression is associated with mucinous differentiation. Oncol Rep, 2007, 17(5): 1101-1107

[84] Feng M, Chen JY, Weissman-Tsukamoto R, et al.. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A, 2015, 112(7): 2145-2150

[85] Truxova I, Kasikova L, Salek C, et al.. Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020, 105(7): 1868-1878

[86] Sen Santara S, Lee DJ, Crespo Â, et al.. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature, 2023, 616(7956): 348-356

[87] Peng RQ, Chen YB, Ding Y, et al.. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol, 2010, 16(19): 2428-2434

[88] Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol, 2008, 181(4): 2533-2543

[89] Zamanian M, Qader Hamadneh LA, Veerakumarasivam A, et al.. Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways. Cancer Cell Int, 2016, 16: 56

[90] Cheng WF, Hung CF, Chai CY, et al.. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest, 2001, 108(5): 669-678

[91] Gong Z, Chen M, Miao J, et al.. Calreticulin as an adjuvant in vivo to promote dendritic cell maturation and enhance antigen-specific T lymphocyte responses against melanoma. J Immunol Res, 2022, 2022: 8802004

[92] Gameiro SR, Jammeh ML, Wattenberg MM, et al.. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget, 2014, 5(2): 403-416

[93] Padariya M, Kalathiya U, Houston DR, et al.. Recognition dynamics of cancer mutations on the ERp57-tapasin interface. Cancers, 2020, 12(3): 737

[94] Liu Y, Wang JX, Nie ZY, et al.. Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop. J Exp Clin Cancer Res, 2019, 38(1): 439

[95] Basu A, Cajigas-Du Ross CK, Rios-Colon L, et al.. LEDGF/p75 overexpression attenuates oxidative stress-induced necrosis and upregulates the oxidoreductase ERP57/PDIA3/GRP58 in prostate cancer. PLoS One, 2016, 11(1): e0146549

[96] Ocklenburg T, Neumann F, Wolf A, et al.. In oxygen-deprived tumor cells ERp57 provides radioprotection and ensures proliferation via c-Myc, PLK1 and the AKT pathway. Sci Rep, 2021, 11: 7199

[97] Hussmann M, Janke K, Kranz P, et al.. Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits proliferation and increases sensitivity to ionizing radiation and chemotherapeutics. Oncotarget, 2015, 6(36): 39247-39261

[98] Hu Q, Ye Y, Chan LC, et al.. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol, 2019, 20(7): 835-851

[99] Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today, 2000, 21(9): 455-464

[100] Seliger B, Harders C, Lohmann S, et al.. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol, 1998, 28(1): 122-133

[101] Vitale M, Rezzani R, Rodella L, et al.. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res, 1998, 58(4): 737-742

[102] Kageshita T, Hirai S, Ono T, et al.. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol, 1999, 154(3): 745-754

[103] Alpan RS, Zhang M, Pardee AB. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res, 1996, 56(19): 4358-4361

[104] Ritz U, Seliger B. The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance. Mol Med, 2001, 7(3): 149-158

[105] Zhu K, Wang J, Zhu J, et al.. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene, 1999, 18(54): 7740-7747

[106] Seliger B, Höhne A, Jung D, et al.. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol, 1997, 25(7): 608-614

[107] Restifo NP, Esquivel F, Kawakami Y, et al.. Identification of human cancers deficient in antigen processing. J Exp Med, 1993, 177(2): 265-272

[108] Wolpert EZ, Petersson M, Chambers BJ, et al.. Generation of CD8⁺ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci U S A, 1997, 94(21): 11496-11501

[109] Dissemond J, Kothen T, Mörs J, et al.. Downregulation of tapasin expression in progressive human malignant melanoma. Arch Dermatol Res, 2003, 295(2): 43-49

[110] Raffaghello L, Prigione I, Bocca P, et al.. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene, 2005, 24(29): 4634-4644

[111] Atkins D, Breuckmann A, Schmahl GE, et al.. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer, 2004, 109(2): 265-273

[112] Thuring C, Follin E, Geironson L, et al.. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma. Br J Cancer, 2015, 113(11): 1640

[113] Garbi N, Tan P, Diehl AD, et al.. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol, 2000, 1(3): 234-238

[114] Grandea AG, Golovina TN, Hamilton SE, et al.. Impaired assembly yet normal trafficking of MHC class I molecules in tapasin mutant mice. Immunity, 2000, 13(2): 213-222

[115] Facoetti A, Nano R, Zelini P, et al.. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res, 2005, 11(23): 8304-8311

[116] Lou Y, Vitalis TZ, Basha G, et al.. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res, 2005, 65(17): 7926-7933

[117] Han LY, Fletcher MS, Urbauer DL, et al.. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res, 2008, 14(11): 3372-3379

[118] Thuring C, Geironson L, Paulsson K. Tapasin and human leukocyte antigen class I dysregulation correlates with survival in glioblastoma multiforme. Anticancer Agents Med Chem, 2014, 14(8): 1101-1109

[119] Jiang Q, Pan HY, Ye DX, et al.. Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome. Tumor Biol, 2010, 31(5): 451-459

[120] Song D, Liu H, Wu J, et al.. Insights into the role of ERp57 in cancer. J Cancer, 2021, 12(8): 2456-2464

[121] Cheng K, Lee JS, Hao P, et al.. Tetrazole-based probes for integrated phenotypic screening, affinity-based proteome profiling, and sensitive detection of a cancer biomarker. Angew Chim Int Ed, 2017, 56(47): 15044-15048

[122] Chignard N, Shang S, Wang H, et al.. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: detection of generated fragments in patient sera. Gastroenterology, 2006, 130(7): 2010-2022

[123] Liao CJ, Wu TI, Huang YH, et al.. Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci, 2011, 102(12): 2255-2263

[124] Chay D, Cho H, Lim BJ, et al.. ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. Int J Oncol, 2010, 37(2): 399-412

[125] Pressinotti NC, Klocker H, Schäfer G, et al.. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer, 2009, 8: 130

[126] Linge A, Kennedy S, O’Flynn D, et al.. Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not. Invest Ophthalmol Vis Sci, 2012, 53(8): 4634-4643

[127] Leys CM, Nomura S, LaFleur BJ, et al.. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery, 2007, 141(1): 41-50

[128] Shimoda T, Wada R, Kure S, et al.. Expression of protein disulfide isomerase A3 and its clinicopathological association in gastric cancer. Oncol Rep, 2019, 41(4): 2265-2272

[129] Ren H, Du N, Liu G, et al.. Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol, 2006, 12(17): 2789-2792

[130] Androlewicz MJ. The role of tapasin in MHC class I antigen assembly. Immunol Res, 1999, 20(2): 79-88

[131] Garbi N, Tanaka S, Momburg F, et al.. Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol, 2006, 7(1): 93-102

[132] Ye L, Park JJ, Dong MB, et al.. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat Biotechnol, 2019, 37(11): 1302-1313

[133] Li S, Zhao X, Chang S, et al.. ERp57-small interfering RNA silencing can enhance the sensitivity of drug-resistant human ovarian cancer cells to paclitaxel. Int J Oncol, 2019, 54(1): 249-260

[134] Lovat PE, Corazzari M, Armstrong JL, et al.. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res, 2008, 68(13): 5363-5369

[135] Corazzari M, Lovat PE, Armstrong JL, et al.. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer, 2007, 96(7): 1062-1071

[136] Bernardini M, Lee CH, Beheshti B, et al.. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia, 2005, 7(6): 603-613

[137] Cicchillitti L, di Michele M, Urbani A, et al.. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res, 2009, 8(4): 1902-1912

[138] Choe MH, Min JW, Jeon HB, et al.. ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer. Oncotarget, 2015, 6(5): 2654-2666

[139] Bourougaa K, Naski N, Boularan C, et al.. Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. Mol Cell, 2010, 38(1): 78-88

[140] Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers, 2014, 6(2): 897-925

[141] Chichiarelli S, Gaucci E, Ferraro A, et al.. Role of ERp57 in the signaling and transcriptional activity of STAT3 in a melanoma cell line. Arch Biochem Biophys, 2010, 494(2): 178-183

[142] Eufemi M, Coppari S, Altieri F, et al.. ERp57 is present in STAT3–DNA complexes. Biochem Biophys Res Commun, 2004, 323(4): 1306-1312

[143] Gu F, Ma Y, Zhang Z, et al.. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep, 2010, 23(3): 671-676

[144] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000, 100(1): 57-70

[145] Goicoechea S, Pallero MA, Eggleton P, et al.. The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. J Biol Chem, 2002, 277(40): 37219-37228

[146] Schumacher TN, Hacohen N. Neoantigens encoded in the cancer genome. Curr Opin Immunol, 2016, 41: 98-103

[147] Yarchoan M, Johnson BA, Lutz ER, et al.. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer, 2017, 17(4): 209-222

[148] Yadav M, Jhunjhunwala S, Phung QT, et al.. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature, 2014, 515(7528): 572-576

[149] Marijt KA, Doorduijn EM, van Hall T. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I^low cancers. Mol Immunol, 2019, 113: 43-49

[150] Riaz N, Havel JJ, Makarov V, et al.. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell, 2017, 171(4): 934-949.e16

[151] Verdegaal EME, de Miranda NFCC, Visser M, et al.. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature, 2016, 536(7614): 91-95

[152] Galon J, Costes A, Sanchez-Cabo F, et al.. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 2006, 313(5795): 1960-1964

[153] Ackerman AL, Kyritsis C, Tampé R, et al.. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci U S A, 2003, 100(22): 12889-12894

[154] McCluskey J, Rossjohn J, Purcell AW. TAP genes and immunity. Curr Opin Immunol, 2004, 16(5): 651-659

[155] Di Leva G, Garofalo M, Croce CM. microRNAs in cancer. Annu Rev Pathol, 2014, 9: 287-314

[156] Hayes J, Peruzzi PP, Lawler S. microRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med, 2014, 20(8): 460-469

[157] Sayed D, Abdellatif M. microRNAs in development and disease. Physiol Rev, 2011, 91(3): 827-887

[158] Neefjes J, Jongsma MLM, Paul P, et al.. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol, 2011, 11(12): 823-836

[159] Del Cid N, Jeffery E, Rizvi SM, et al.. Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J Biol Chem, 2010, 285(7): 4520-4535

[160] Aptsiauri N, Cabrera T, Garcia-Lora A, et al. MHC class I antigens and immune surveillance in transformed cells. International Review of Cytology. Amsterdam: Elsevier; 2007:139–189.

[161] Turcotte S, Katz SC, Shia J, et al.. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. Cancer Immunol Res, 2014, 2(6): 530-537

[162] Guo YE, Riley KJ, Iwasaki A, et al.. Alternative capture of noncoding RNAs or protein-coding genes by herpesviruses to alter host T cell function. Mol Cell, 2014, 54(1): 67-79

[163] Min S, Li L, Zhang M, et al.. TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. Genes Immun, 2012, 13(8): 621-631

[164] Wu X, Li T, Jiang R, et al.. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer, 2023, 22(1): 194

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology

Just Accepted

This article has successfully passed peer review and final editorial review, and will soon enter typesetting, proofreading and other publishing processes. The currently displayed version is the accepted final manuscript. The officially published version will be updated with format, DOI and citation information upon launch. We recommend that you pay attention to subsequent journal notifications and preferentially cite the officially published version. Thank you for your support and cooperation.